Logo image of ARGX

ARGENX SE - ADR (ARGX) Stock Fundamental Analysis

USA - NASDAQ:ARGX - US04016X1019 - ADR

829.46 USD
+12.14 (+1.49%)
Last: 10/27/2025, 1:38:00 PM
Fundamental Rating

6

Overall ARGX gets a fundamental rating of 6 out of 10. We evaluated ARGX against 534 industry peers in the Biotechnology industry. While ARGX has a great health rating, its profitability is only average at the moment. ARGX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make ARGX suitable for growth investing!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

ARGX had positive earnings in the past year.
ARGX had a positive operating cash flow in the past year.
ARGX had negative earnings in 4 of the past 5 years.
ARGX had a negative operating cash flow in each of the past 5 years.
ARGX Yearly Net Income VS EBIT VS OCF VS FCFARGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

ARGX has a better Return On Assets (17.84%) than 96.25% of its industry peers.
ARGX has a better Return On Equity (21.00%) than 95.69% of its industry peers.
The Return On Invested Capital of ARGX (6.01%) is better than 93.07% of its industry peers.
Industry RankSector Rank
ROA 17.84%
ROE 21%
ROIC 6.01%
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ARGX Yearly ROA, ROE, ROICARGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30 -40

1.3 Margins

ARGX has a better Profit Margin (41.97%) than 98.31% of its industry peers.
The Operating Margin of ARGX (15.30%) is better than 93.63% of its industry peers.
With an excellent Gross Margin value of 89.40%, ARGX belongs to the best of the industry, outperforming 91.20% of the companies in the same industry.
Industry RankSector Rank
OM 15.3%
PM (TTM) 41.97%
GM 89.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARGX Yearly Profit, Operating, Gross MarginsARGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

7

2. Health

2.1 Basic Checks

ARGX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ARGX has been increased compared to 1 year ago.
The number of shares outstanding for ARGX has been increased compared to 5 years ago.
Compared to 1 year ago, ARGX has a worse debt to assets ratio.
ARGX Yearly Shares OutstandingARGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ARGX Yearly Total Debt VS Total AssetsARGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 29.39 indicates that ARGX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 29.39, ARGX belongs to the top of the industry, outperforming 93.26% of the companies in the same industry.
ARGX has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
ARGX's Debt to FCF ratio of 0.14 is amongst the best of the industry. ARGX outperforms 96.44% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.01, ARGX perfoms like the industry average, outperforming 45.69% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.14
Altman-Z 29.39
ROIC/WACC0.8
WACC7.52%
ARGX Yearly LT Debt VS Equity VS FCFARGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

ARGX has a Current Ratio of 5.60. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ARGX (5.60) is better than 60.30% of its industry peers.
ARGX has a Quick Ratio of 5.27. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX has a Quick ratio (5.27) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.6
Quick Ratio 5.27
ARGX Yearly Current Assets VS Current LiabilitesARGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 345.45% over the past year.
The Revenue has grown by 56.80% in the past year. This is a very strong growth!
Measured over the past years, ARGX shows a very strong growth in Revenue. The Revenue has been growing by 94.61% on average per year.
EPS 1Y (TTM)345.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%731.11%
Revenue 1Y (TTM)56.8%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%97.62%

3.2 Future

Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 103.72% on average per year.
ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.89% yearly.
EPS Next Y805.38%
EPS Next 2Y278.4%
EPS Next 3Y166.67%
EPS Next 5Y103.72%
Revenue Next Year85.31%
Revenue Next 2Y56.35%
Revenue Next 3Y43.79%
Revenue Next 5Y32.89%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ARGX Yearly Revenue VS EstimatesARGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ARGX Yearly EPS VS EstimatesARGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 40 60 80 100

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 90.06, the valuation of ARGX can be described as expensive.
Based on the Price/Earnings ratio, ARGX is valued cheaper than 91.20% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.89. ARGX is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 31.41, which means the current valuation is very expensive for ARGX.
ARGX's Price/Forward Earnings ratio is rather cheap when compared to the industry. ARGX is cheaper than 91.01% of the companies in the same industry.
ARGX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.99.
Industry RankSector Rank
PE 90.06
Fwd PE 31.41
ARGX Price Earnings VS Forward Price EarningsARGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ARGX is valued cheaply inside the industry as 90.07% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ARGX indicates a rather cheap valuation: ARGX is cheaper than 91.57% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 165.42
EV/EBITDA 91.23
ARGX Per share dataARGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

ARGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ARGX's earnings are expected to grow with 166.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y278.4%
EPS Next 3Y166.67%

0

5. Dividend

5.1 Amount

ARGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ARGENX SE - ADR

NASDAQ:ARGX (10/27/2025, 1:38:00 PM)

829.46

+12.14 (+1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners41.51%
Inst Owner Change-0.6%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap51.07B
Revenue(TTM)3.05B
Net Income(TTM)1.28B
Analysts84.8
Price Target853.34 (2.88%)
Short Float %3.02%
Short Ratio5.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14.45%
Revenue beat(16)13
Avg Revenue beat(16)17.87%
PT rev (1m)-0.49%
PT rev (3m)7.7%
EPS NQ rev (1m)-1.94%
EPS NQ rev (3m)22.09%
EPS NY rev (1m)-0.6%
EPS NY rev (3m)32.96%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)11.61%
Revenue NY rev (1m)0.96%
Revenue NY rev (3m)12.44%
Valuation
Industry RankSector Rank
PE 90.06
Fwd PE 31.41
P/S 16.74
P/FCF 165.42
P/OCF 126.48
P/B 8.38
P/tB 8.69
EV/EBITDA 91.23
EPS(TTM)9.21
EY1.11%
EPS(NY)26.41
Fwd EY3.18%
FCF(TTM)5.01
FCFY0.6%
OCF(TTM)6.56
OCFY0.79%
SpS49.55
BVpS99.01
TBVpS95.45
PEG (NY)0.11
PEG (5Y)N/A
Graham Number143.24
Profitability
Industry RankSector Rank
ROA 17.84%
ROE 21%
ROCE 7.61%
ROIC 6.01%
ROICexc 16.72%
ROICexgc 18.56%
OM 15.3%
PM (TTM) 41.97%
GM 89.4%
FCFM 10.12%
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.14
Debt/EBITDA 0.07
Cap/Depr 428.74%
Cap/Sales 3.12%
Interest Coverage 519.07
Cash Conversion 82.6%
Profit Quality 24.11%
Current Ratio 5.6
Quick Ratio 5.27
Altman-Z 29.39
F-Score5
WACC7.52%
ROIC/WACC0.8
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)345.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%731.11%
EPS Next Y805.38%
EPS Next 2Y278.4%
EPS Next 3Y166.67%
EPS Next 5Y103.72%
Revenue 1Y (TTM)56.8%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%97.62%
Revenue Next Year85.31%
Revenue Next 2Y56.35%
Revenue Next 3Y43.79%
Revenue Next 5Y32.89%
EBIT growth 1Y207%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1305.72%
EBIT Next 3Y205.97%
EBIT Next 5Y117.35%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.79%
OCF growth 3YN/A
OCF growth 5YN/A

ARGENX SE - ADR / ARGX FAQ

What is the fundamental rating for ARGX stock?

ChartMill assigns a fundamental rating of 6 / 10 to ARGX.


What is the valuation status of ARGENX SE - ADR (ARGX) stock?

ChartMill assigns a valuation rating of 6 / 10 to ARGENX SE - ADR (ARGX). This can be considered as Fairly Valued.


Can you provide the profitability details for ARGENX SE - ADR?

ARGENX SE - ADR (ARGX) has a profitability rating of 5 / 10.


Can you provide the expected EPS growth for ARGX stock?

The Earnings per Share (EPS) of ARGENX SE - ADR (ARGX) is expected to grow by 805.38% in the next year.